If you're buying NuVasive products for a surgical center, don't focus only on the implants. The mistakes I've made—and the ones I've watched others make—come from ignoring the support system around the product: infection control, surgical lighting, and the clinical services attached to the Globus Medical NuVasive merger. Those 'secondary' decisions cost me roughly $12,500 in wasted work, reorders, and delays. Here's the breakdown, so you don't repeat it.
I'm a supply chain coordinator for a spine surgery service. I've been handling equipment orders since 2018. I'm not a surgeon or a lab tech—I just know what it costs to bring everything together before the surgeon walks into the OR. I've personally made (and documented) seven significant procurement mistakes. One of the most avoidable: in June 2022, I ignored a clinician's request for PCR-based MRSA screening because I didn't see how it fit into our spine surgery workflow. That's on me. These days I maintain our team's pre-purchase checklist, which has caught 47 potential errors in the past 18 months. The checklist isn't complicated, but it keeps me honest.
The Globus Medical NuVasive Merger Is a Bigger Deal Than I Thought
From the outside, the Globus Medical NuVasive merger reads as a routine device company consolidation. The reality is more interesting. The deal, completed in September 2023, put NuVasive's MIS technique education and clinical services alongside Globus's robotics, navigation, and implant portfolio. As a buyer, that changes what 'NuVasive products' means. It's not just ALIF, TLIF, XLIF, or ACDF implants. It can be a full surgical ecosystem.
When the merger was announced, most procurement managers asked, 'Who do I send the PO to?' I made the same mistake. I treated the merger as a price-list update. I didn't ask the combined clinical team what training they now offered, which navigation platforms paired best with which implants, or how case support could shorten the learning curve for surgeons new to MIS. In Q3 2024, I finally sat down with the reps and realized we were underusing the services already in our contract. We caught up eventually, but we lost months of potential efficiency.
Infection Control Products Are Not a Commodity
The second thing I underestimated: infection control product choices are not throwaway decisions. Surgical site infections (SSIs) are among the most common healthcare-associated infections in surgical patients, according to CDC. Prevention isn't just drapes and antiseptics. It's also screening patients before surgery—and that's where PCR comes in.
How Does PCR Work? Brief Version
PCR stands for polymerase chain reaction. In simple terms, it uses enzymes and temperature changes to create millions of copies of a specific DNA sequence. If MRSA or another pathogen is present, the test amplifies its genetic material enough to be detected quickly. Traditional culture can take days; PCR can return results in hours. That speed changes clinical decisions—including whether to adjust antibiotics before a spinal procedure.
Our infection control team asked for a PCR-based MRSA screening protocol in 2022. I stalled because I thought our existing swab method covered it. It didn't. The culture-based method took days, which was too slow for a pre-op timeline. By the time we implemented PCR screening, three months had passed, and the credibility gap was real. No patient developed an infection, and I'm grateful for that. But the delay was 100% avoidable, and the lesson stayed with me: a great implant system can be undermined by a weak infection control loop.
Surgical Lights: The $4,000 Oversight
Another assumption that burned me: surgical lights are all more or less the same. They're not.
In early 2024, I approved a budget-tier surgical light based on a brochure and a low quote. I didn't ask the surgeons about color rendering index (CRI) or whether the light would cause shadows in a deep, narrow MIS spine incision. The result: uneven illumination, washed-out tissue colors, and a lot of frustration during cases. We spent roughly $4,000 reconfiguring the room with a better light. (Yes, that still stings.)
For spine surgery, lighting guidance like AORN's recommendations highlights consistent illumination, adjustable color temperature, and a high CRI—typically in the 90s. A light that looks acceptable in a brochure can perform very differently in a dark OR. What cost us wasn't just the budget light. It was the lost time and the waiting physician.
My Current Procurement Checklist
After those failures, I built a checklist. It's not fancy, but it forces me to slow down. Here's the core:
- Clinical support review: Does the NuVasive / Globus Medical product include the training, case support, and integration services our surgeons need?
- Infection control product alignment: Does the product fit our SSI prevention workflow? Do we have the lab capacity and turnaround time for screening?
- PCR screening workflow: Are we using the right assay and sample type? Can results arrive before surgery, when they can still change the plan?
- Surgical light testing: Have surgeons seen the light in a real OR? What are the CRI, color temperature, and illuminance specs?
- Implants and navigation compatibility: Do the NuVasive products work with the navigation platform and technique the surgeon actually uses?
The counterintuitive part: spinal implants go through intense regulatory scrutiny, but in my role, the avoidable problems show up in the unglamorous infrastructure—infection control logistics, PCR turnaround time, and surgical lights.
Where This Might Not Apply
I'll be honest about the limits. If you're at a large academic center, you may already have clinical engineering teams defining light specs and infection control specialists managing PCR screening. If so, this may sound basic. If you're an ambulatory surgery center with low baseline infection rates, PCR screening may not be worth the cost. That's a local call. Also, NuVasive and Globus Medical continue to evolve the combined portfolio, so verify current models, service scope, and pricing before you rely on any of my specifics.
The core message is what I keep coming back to: buying a great spinal implant is not the same as buying a great surgical outcome. The outcome depends on the system around it—including infection control products, PCR screening, and even the surgical light.
